BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology)(BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology)) - 药物靶点：BCMA x GPRC5D_在研适应症：复发性多发性骨髓瘤，难治性多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

CAR-T

别名

BCMA/GPRC5D double CAR-T

靶点

BCMA x GPRC5D

作用机制

BCMA调节剂(B细胞成熟蛋白调节剂)、GPRC5D调节剂(G蛋白偶联受体家族C组5成员D调节剂)、免疫细胞毒性

治疗领域

肿瘤免疫系统疾病心血管疾病+ [2]

在研适应症

复发性多发性骨髓瘤难治性多发性骨髓瘤

非在研适应症-

原研机构

广州百暨基因科技有限公司

在研机构

广州百暨基因科技有限公司

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评-

登录后查看时间轴

关联

3

项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的临床试验

NCT06515262 / RecruitingN/AIIT

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.

开始日期2024-07-01

申办/合作机构

中国人民解放军联勤保障部队第九二〇医院

[+1]

NCT06068400 / RecruitingN/A

A Single-Arm, Single-Center Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

This is a single arm, single center clinical study evaluating the safety and efficacy of CAR-T treatment for multiple myeloma.

开始日期2023-09-13

申办/合作机构

广州百暨基因科技有限公司

NCT05998928 / Recruiting临床2期IIT

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With R/R MM Who Received Three or More Lines of Therapy

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.

开始日期2023-07-27

申办/合作机构

Wuhan Xiehe Hospital Tower

[+1]

100 项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的临床结果

登录后查看更多信息

100 项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的转化医学

登录后查看更多信息

100 项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的专利（医药）

登录后查看更多信息

100 项与 BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) 相关的药物交易

登录后查看更多信息